Unlike common nutraceuticals stocked in every health store, CJC-1295 reaches researchers through a dedicated online market that Witta residents reach through online vendors. The key implication for Witta researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. What follows is a practical research guide built specifically around CJC-1295, covering everything a Witta researcher needs before placing a first order.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Witta comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger serious immune reactions even at very low concentrations. Signs of a credible vendor beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. For Witta researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Witta
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with sterile bacteriostatic water. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results stated as EU/mg and compare against acceptable research limits for your application. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
